<?xml version="1.0" encoding="UTF-8"?>
<p>In Europe, after HCV therapy with interferon (IFN), 530 patients were followed prospectively for a median of 8.4 years. Of these, 192 (36%) had achieved sustained virological response (SVR). Whereas liver-related mortality rose to 30% in those who did not achieve SVR, there were only a handful of deaths in the SVR group. Mike summarised the outlook for an IFN-free cure ‘Many of the thought leaders said that the challenge was so great, it would never be overcome until the mid-2020’s’.</p>
